Reports: Court upholds Abilify patent

NEW YORK — A generic version of a schizophrenia drug made by Otsuka Holdings and Bristol-Myers Squibb can't be launched until April 2015, according to published reports.



Bloomberg reported that the U.S. Court of Appeals for the Federal Circuit upheld the validity of patents covering Abilify (aripiprazole) in the two companies' lawsuit against Teva Pharmaceutical Industries and Apotex.



According to IMS Health, Abilify was the fourth top-selling drug in the United States in 2011, with sales of $5.2 billion.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.